A biologics CDMO RFP should do more than collect capabilities, timelines and prices. At late stage, the purpose of the request is to reveal how a potential partner will execute the program when the science, quality requirements and commercial pressures become real.
Generic questions usually generate generic responses. Almost every qualified provider can describe GMP facilities, experienced teams and broad CDMO services.
Those statements matter, but they do not show whether the proposed site understands your process, whether the analytical package can support release, or how the team will respond when new data changes the plan.
A stronger RFP gives the CDMO enough context to think, challenge assumptions and propose a workable route. It also makes competing proposals easier to compare because each bidder responds to the same operational reality.
Begin with the program story, not the service list
Many RFPs start with a table of requested activities. The sponsor lists technology transfer, engineering runs, GMP manufacturing, analytical testing and fill and finish. Providers then estimate each line independently.
However, biologics production rarely behaves like a set of disconnected tasks.
The cell line, upstream process, downstream strategy, analytical methods, formulation, container closure system and regulatory history all influence one another.
Start the RFP with a concise narrative that explains where the program is today, what has already been demonstrated and what must happen next. Include the intended indication, current development phase, target markets, expected filing strategy and supply milestone.
Then describe the biological product, expression system, process scale, available cell banks or plasmid DNA constructs, current specifications and known process sensitivities.
This context helps the CDMO understand why the work matters. More importantly, it allows the technical team to identify dependencies that a procurement table may miss.
Separate fixed requirements from open decisions
Late stage does not mean every decision is closed.
In fact, some of the most valuable CDMO input appears when the sponsor clearly distinguishes between what must remain unchanged and what can still improve.
For example, the expression system or cell line may already support clinical data and therefore require a strong justification for change. By contrast, a buffer, hold time, chromatography step or sampling strategy may still allow optimization.
The same applies to cell line development for programs that have not yet locked the production platform.
The RFP should clearly identify four types of information.
First, fixed elements that the selected partner must reproduce.
Second, preferred elements that may change with scientific justification.
Third, open questions where the sponsor expects a recommendation.
Finally, known risks that require evaluation during transfer.
This approach produces more useful proposals. It also reveals whether a CDMO simply accepts the package or engages with the science from day one.
Ask for a site specific execution pathway
A network level capability statement does not confirm that the proposed manufacturing site can deliver the program.
The RFP should ask each bidder to identify the actual site, equipment scale, manufacturing line and supporting laboratories included in the proposal.
Then ask the CDMO to explain the sequence from onboarding to released GMP material. The response should cover data review, gap assessment, method transfer, raw material qualification, process transfer, engineering work, manufacturing, deviation management, testing, QA review and release.
For commercial or registration work, the proposal should also describe how the site would approach process characterization, qualification activities, continued process verification and future changes.
The objective is not to force every provider into the same technical solution. It is to see whether the proposed route remains coherent from the first activity to the final supply milestone.
Make every assumption visible
Two CDMO proposals can appear comparable while relying on very different assumptions.
One may include method validation, reference standard qualification and stability work. Another may assume the sponsor will provide validated methods, qualified standards and final protocols.
Therefore, the RFP should require a dedicated assumptions section.
Ask bidders to state what they expect the sponsor to provide, which methods they consider ready for transfer, which activities remain provisional and which costs depend on data review.
Also request a list of exclusions and potential change order triggers.
This does not indicate a lack of confidence. On the contrary, it shows commercial discipline and gives both parties a clearer starting point.
A transparent proposal helps the sponsor compare true scope rather than headline price.
Test how quality operates during the project
Late stage teams already know that GMP compliance matters. The more useful question is how quality works during the project.
Ask how the CDMO manages technical and quality decisions, deviations, out of specification results, change controls, investigations and batch disposition.
Clarify when the sponsor participates, who owns each decision and how rapidly information moves between teams.
The RFP should also explore inspection history at the proposed site, quality agreement timing, data integrity controls, document review cycles and support for regulatory questions.
For a biological product moving toward commercial supply, these interactions can influence the schedule as much as the manufacturing run itself.
A strong answer will connect scientific judgment with accountable execution. It should show how the team protects quality without creating avoidable distance between the sponsor and the people doing the work.
Evaluate communication before the project begins
Communication often appears as a soft criterion, yet it has a direct operational effect.
Slow decisions can delay raw material orders, method approvals, deviation closure and manufacturing readiness.
Use the RFP process to test how the CDMO communicates. Ask who will attend governance meetings, whether scientific leads will speak directly with the sponsor, how often project data will be reviewed and what escalation route applies when a milestone is at risk.
You can also request an example governance structure. This should identify the project manager, technical leads, quality contacts and executive sponsor, together with the purpose and frequency of each interaction.
The best model keeps the sponsor close to the detail without requiring them to chase every answer.
Ask how the CDMO handles new information
The initial scope will not survive every new result unchanged.
Analytical transfer may identify a method gap. An engineering batch may expose a hold time limitation. Raw material availability may require an alternative. Clinical progress may change the demand forecast.
The RFP should ask how the CDMO evaluates these developments and converts them into decisions.
A useful response will describe the technical assessment, change control process, impact evaluation, commercial discussion and approval route. It should also explain how the team protects the critical path while resolving the issue.
This is particularly important for complex or non-standard biological products. A rigid operating model may protect the original scope while allowing the wider program to stall.
By contrast, an adaptable partner can preserve quality while reshaping the route around the new information.
Look beyond the first GMP batch
A late stage RFP should examine the path after initial manufacturing.
The selected partner may need to support process performance qualification, launch inventory, routine manufacturing, lifecycle improvements or expansion into additional markets.
Ask how the CDMO would manage increasing demand, additional manufacturing slots, alternative scales and future process changes. Also explore whether development, manufacturing, analytics and aseptic fill and finish can remain connected.
For recombinant proteins, this may involve moving from process optimization into microbial or mammalian GMP production.
For advanced therapy supply chains, it may require integrating plasmid DNA manufacturing with the wider program schedule.
Continuity does not mean that every activity must remain in one building. It means that responsibilities, knowledge and decisions stay connected as the program advances.
Ask for commercial clarity, not only a total price
A useful commercial proposal should show how the CDMO constructed the price.
The response should distinguish fixed activities, estimated work, pass through costs, optional tasks and sponsor responsibilities. Payment milestones and cancellation conditions should also reflect the real sequence of the project.
In addition, ask how the CDMO will handle scope changes, annual price adjustments, material cost fluctuations and future manufacturing campaigns.
A low initial quotation may become less attractive if it relies on narrow assumptions or leaves critical activities unpriced.
Commercial transparency allows the sponsor to model the expected cost rather than approve an incomplete total.
Score execution, not presentation
A polished proposal can still leave critical questions unanswered.
Before issuing the RFP, define the evaluation criteria and apply them consistently. A practical scorecard should consider scientific fit, quality and regulatory confidence, operational feasibility, timeline credibility, commercial transparency, communication model and long term continuity.
Price remains important, but it should sit beside the assumptions and risks that shape the final cost.
During bidder meetings, return to the most important gaps. Ask the technical team to explain how they reached the proposed strategy.
Look for clear reasoning, not only confident language.
This is where scientific depth becomes visible. A credible partner should simplify complex decisions without oversimplifying the program.
Final thoughts
A late stage biologics CDMO RFP should help the sponsor answer one central question: can this team take ownership of the work and keep the program moving when the stakes increase?
The strongest RFPs provide enough information for thoughtful technical input, make assumptions visible and test how the relationship will operate in practice.
As a result, they distinguish a capable vendor from a partner that can support the program through GMP manufacturing and commercial growth.
At 53Biologics, we work side by side with biotech teams across process development, biologics manufacturing, analytics, quality control and fill and finish. Our approach stays close to the science, adapts as programs evolve and protects continuity from one stage to the next.
If you are preparing an RFP for a protein, plasmid DNA or another biological product, contact our team to discuss the technical information that will help us build a clear, realistic proposal.
About 53Biologics:
53Biologics is the end-to-end biologics CDMO built to keep progress moving. We combine scientific expertise, integrated in-house capabilities and a close, hands-on way of working to help biotech teams make confident decisions, adapt as programs evolve and stay with one partner from early development through commercialization. With process development, manufacturing, analytics and fill-finish connected under one system, we reduce handoffs, protect continuity and help clients grow without disruption. We were made for this.
For more information or to speak with one of our experts email us at [email protected]